2022 NYSE IPO Summit
March 11, 2022
Lu Alleruzzo co-founder and CEO of Immunophotonics attended the NYSE 9th Annual 2022 IPO Summit. Very inspiring to hear from…
2022 St. Louis Dealmaker of the Year
March 4, 2022
The continued success of Immunophotonics is driven by the dedication and hard work of our team. Immunophotonics was one of…
Immunophotonics Awarded $2.4 Million SBIR Grant by the National Cancer Institute
February 17, 2022
Immunophotonics, Inc. was recently awarded a Small Business Innovative Research (SBIR) Phase I and Phase II Fast-Track grant for research…
Wei R. Chen B Cell Paper Publication
February 4, 2022
Hot off the press: Another part of the mechanism of action of how IP-001 (GC) remodels the tumor microenvironment revealed!…
SPIE Photonics West and BiOS Expo, Jan 22 – 27 in San Francisco
January 21, 2022
If you are interested in the interface between cancer immunotherapy innovation and photonics, then catch up with Tomas Hode, PhD,…
USPTO Issues Patent Covering Immunophotonics’ Lead Drug Candidate, IP-001
September 14, 2021
Immunophotonics is pleased to announce that the United States Patent and Trademark has issued U.S. Patent No. 11111316, which covers…
Immunophotonics Switzerland (IPS Biopharma) Invited to Present at Swiss Biotech Day
September 7, 2021
Immunophotonics Switzerland (IPS Biopharma) will be presenting at the Swiss Biotech Day in the Emerging Company session hosted by BB…
Immunophotonics Publishes Follow-up Feature in Nature Biopharma Dealmakers
September 1, 2021
Immunophotonics is excited to be featured in the September 2021 oncology issue of Nature Biopharma Dealmakers. Read what Dr. Markus…
Immunophotonics Featured in Nature Biopharma Dealmakers
March 1, 2021
Immunophotonics has been featured in the March oncology issue of Nature Biopharma Dealmakers (https://www.nature.com/articles/d43747-021-00020-2 ). Nature selects only a handful…
Study Shows IP-001 to Amplify Tumoricidal and Immune Effect of Cancer Ablation Therapies
February 25, 2021
A paper recently published in Cells has described how Immunophotonics' immune-stimulating drug IP-001 was shown to be effective against metastatic…